VRTX logo
VRTX
Vertex Pharmaceuticals

Gene Editing And Precision Medicines Will Serve Aging Populations

Published
08 Apr 25
Updated
20 Aug 25
AnalystHighTarget's Fair Value
US$618.10
36.1% undervalued intrinsic discount
20 Aug
US$395.12
Loading
1Y
-18.1%
7D
1.3%

Author's Valuation

US$618.1

36.1% undervalued intrinsic discount

AnalystHighTarget Fair Value

Narrative
Updates4

Shared on07 May 25
Fair value Decreased 0.20%

Read more

Shared on30 Apr 25
Fair value Increased 0.39%

AnalystHighTarget made no meaningful changes to valuation assumptions.

Read more

Shared on23 Apr 25
Fair value Increased 8.79%

AnalystHighTarget made no meaningful changes to valuation assumptions.

Read more

Shared on16 Apr 25
Fair value Decreased 8.68%

AnalystHighTarget has decreased revenue growth from 13.9% to 12.3%.

Read more